You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is a global company headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Patients and customers benefit from Grünenthal products in around 100 countries worldwide. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 bn.
Grünenthal is driven by a clear and ambitious vision: a World Free of Pain. In 2025, we made significant progress in advancing innovative medicines for patients living with pain worldwide.
The Grünenthal Report is a key way we share updates on our collective projects, priorities, and progress. It provides an overview of our continued efforts to move closer to our vision.
